Analyst Insights

Advanced Micro Devices (AMD) Stock Remains Attractive as Long-Term Confidence Increases, Says Top Analyst

Advanced Micro Devices (AMD) is getting yet another vote of confidence, as Cowen’s top analyst Matt Ramsay raised his target price on AMD from $30 to …

Why This Top Analyst Just Upgraded Roku Inc (ROKU) Stock

Roku Inc (ROKU) stock nearly quadrupled in value between November of last year and the beginning of October. However, like many of peers …

2 Notable Biotech Calls

It has not been a good day for investors this Thursday.  Worries about trade, the situation in Saudi Arabia, plunging oil prices, falling …

Top Analyst Pulls Back Price Target on Alibaba (BABA) Stock Ahead of Earnings

Alibaba (BABA) is due to release its quarterly results on Friday, November 2. This is an event that is sure to be closely watched …

Why Facebook (FB) Biggest Bear Sees an 18% Stock Decline

What does it take to have Facebook (FB) remove an account? Do you have to be a sexual harasser?

Netflix (NFLX) Stock Is a Winner, but Valuation Is Pretty Full, Says Top Analyst

Streaming giant Netflix (NFLX) managed to report robust third-quarter numbers that smashed expectations out of the water. The strong numbers provided a lift to …

These Analysts Didn’t Need Another Reason to Stay Sidelined on International Business Machines (IBM) Stock, but They Got It

You typically can have confidence in the consensus opinion. However, with the International Business Machines (IBM) third-quarter earnings report, the consensus was wrong: …

Could General Electric’s (GE) New Chief Lead a Turnaround for the Stock?

As General Electric (GE) welcomes new chief Larry Culp, Cowen’s analyst Gautam Khanna is weighing in on how he expects the company will fare from …

H.C. Wainwright Reiterates Upbeat View of EyePoint Pharmaceuticals (EYPT) Stock on Back of FDA Approval

EyePoint Pharmaceuticals (EYPT) has a big reason to celebrate this week — the Food and Drug Administration (FDA) approved the vision-improving technology. The fluocinolone …

Oppenheimer Pounds the Table on Catalyst Pharmaceuticals (CPRX) Ahead of Upcoming FDA Decision

Oppenheimer analyst Leland Gershell was out pounding the table on shares of Catalyst Pharmaceuticals (CPRX), reiterating a Buy rating and price target of $6.00, which implies …